calcul approach immun checkpoint
therapi initi outperform
immun checkpoint modul undeni posit impact cancer
treatment vanguard immuno-oncolog i/o revolut
howev patient treat current avail checkpoint antibodi fail
achiev respons often tumor util altern pathway suppress
immun system independ signal
believ blockad ancillari checkpoint repres viabl therapeut strategi
relapsed/refractori patient see valu compugen core technolog
identifi novel previous underappreci checkpoint target first-in-
class pvrig inhibitor pois enter clinic mid-year believ
time investor revisit compugen stori initi outperform price target
compugen core compet lie discoveri novel checkpoint
modul iter process comput screen function
assay see next month potenti transform period
compani move lead program anti-pvrig antibodi clinic
pvrig t-cell checkpoint regulatori axi cancer
cell exploit escap immun respons sever compani
anti-tigit antibodi earli clinic develop compugen first
identifi new target pvrig domin player pathway believ
anti-pvrig antibodi may essenti effect drug axi
believ compani abil identifi ration checkpoint combin
may give edg competitor preclin demonstr
synergist anti-tumor activ compugen tigit-target
antibodi well inhibitor expect enter
clinic follow potenti allow compugen flex
i/o muscl combin
compugen discoveri platform serv engin partnership
could help off-set oper cost preced bayer in-licens
antibodi current preclin develop
novel checkpoint discov compugen applic oncolog
checkpoint drive anti-tumor activ independ t-cell
compugen disclos target ident point myeloid
target shown promis clinic
compugen biotechnolog compani
focus emerg field immuno-
oncolog compani develop
novel checkpoint antibodi
cancer autoimmun diseas
analyst certif import disclosur see disclosur appendix
success clinic develop
combin therapi refractory/relaps lung endometri
first regulatori approv combin
risk-adjust revenu approxim
success monotherapi lead earlier-
than-anticip approv commerci
and/or efficaci addit indic
beyond lung endometri cancer
regulatori commerci success addit pipelin
compugen core compet lie discoveri previous
unknown underappreci immun checkpoint
feed compani oncology/autoimmune-focus pipelin
provid engin partnership opportun
valuat center commerci potenti
moncolon antibodi target pvrig tigit
respect preclin antibodi shown activ
assort cancer respond poorli treatment
antibodi next month believ
compani pois gener clinic proof-of-concept
one pvrig-express cancer
potenti initi phase studi monotherapi
mix solid tumor
potenti initi phase studi combin
antibodi
potenti initi clinic studi monotherapi
potenti bayer initi clinic studi
potenti announc new partnership
approv combin narrowly-
defin subset cancer
clinic trial failur safeti concern delay regulatori
price target base risk-adjust revenu ep multipl analysi assum
approv use success commerci profit biotechnolog compani histor trade within averag
sale multipl rang averag ep multipl rang appli multipl estim revenu
multipl estim ep discount period averag result ad project cash per
risk includ price clinic regulatori financ market competit
note see cgen stock trade specul appropri risk toler investor
compugen earli stage biotechnolog compani focus
develop antibodi target immun checkpoint use immuno-
oncolog i/o autoimmun disord headquart israel compugen
oper center holon israel well south san francisco ca
core compet center discoveri valid novel immun
checkpoint util iter process comput predict
function assay compani discoveri platform seed grow
pipelin target antibodi novel checkpoint modul also
use ration identifi synergist combin compugen intern
develop effort focus anti-pvrig antibodi
slate enter clinic compani anti-tigit antibodi
like enter clinic display preclin synergi
product target checkpoint cancer cell exploit down-
regul immun system independ axi compugen
preclin pipelin includ fusion protein
potenti use varieti autoimmun disord sever antibodi
undisclos myeloid target bayer licens right
preclin antibodi also target use oncolog
indic late preclin develop toxic studi
gmp clinic trial materi product current on-going per term
licens agreement bayer compugen entitl receiv
develop commerci mileston payment mid-to-high singl digit
royalti potenti sale
initi coverag compugen outperform rate price
target next month base belief compani
identifi commerci viabl approach treat patient certain cancer
refractori lost respons approv checkpoint
antibodi compugen establish track record identifi novel
immun checkpoint previous unknown under-appreci
compani lead oncolog program focu axi
view next month potenti inflect compani move
clinic
compugen genentech earli identifi tigit novel
checkpoint target see immunol proc
usa today sever biotech compani evalu
tigit inhibitor early-phas clinic trial howev believ compugen
made critic discoveri identifi pvrig import previous
unknown player signal network compani
priorit develop tigit pvrig play similar
role suppress t-cell preclin evid suggest pvrig may
domin two checkpoint certain cancer combin
pvrig tigit antibodi may necessari complet shut
pathway caveat come preclin asset believ
could play import role treat patient
relaps refractori prior treatment checkpoint antibodi
believ compugen well posit implement biomarker-driven strategi
earli clinic trial identifi patient like respond
priori could acceler develop timelin antibodi
valu compugen use discount earn per share revenu multipl
analysi current ascrib valu combin
lung endometri cancer base rel consist
elev express pvrig bind partner tendenc evad
given preclin stage antibodi elect use high discount
rate well low probabl success model
anticip combin could approv us endometri cancer
follow approv non-smal cell lung cancer nsclc
endometri cancer project peak non-risk adjust us sale
peak non-risk adjust eu sale nsclc project peak non-risk
adjust us sale peak non-risk adjust eu sale
detail market model refer exhibit
profit biotechnolog compani histor trade within averag
sale multipl rang averag ep multipl rang
refer cohort profit biopharma compani includ
celgen regeneron recent trade averag sale
averag ep
appli multipl risk-adjust revenu estim
approxim discount period obtain
target price appli multipl ep estim
discount period obtain target price
averag result two method ad project cash per
share obtain price target round
exhibit valuat sensit analysi
valuat compugen base sale project
endometri lung cancer see upsid potenti
sever avenu combin could util broader
rang cancer current model addit current
exclud potenti sale project compugen earli stage asset
includ myeloid checkpoint target well autoimmun
diseas addit exclud potenti mileston payment
royalti bayer relat
drug develop inher riski invest thesi depend
compugen abil success develop manufactur commerci
therapi date compugen run clinic studi
assess regulatori commerci potenti
base preclin result compani may experi delay
complet clinic trial result earli trial may
predict result registr clinic trial
immun checkpoint competit landscap formid sever
compani target axi exampl merck
bristol-my squibb roch anti-tigit antibodi earli clinic
develop compugen abl success develop commerci
antibodi compani may face price pressur
major development-stag biotechnolog compani abil
maintain suffici fund critic develop progress pipelin
candid current compugen cash flow neg model
sever dilut rais may necessari sustain oper potenti
profit microcap stock compugen share rel less
liquid subject rel larger volatil blue chip stock
pipelin clinic program
potenti initi phase studi monotherapi mix solid tumor
potenti initi phase studi combin antibodi
potenti file ind
potenti initi studi monotherapi and/or combin
potenti announc myeloid-target checkpoint pipelin expans
potenti partner autoimmun diseas
potenti bayer begin clinic studi
compani present oppenheim co estim
tumor exploit immun checkpoint
current roster fda-approv checkpoint antibodi target two distinct
atezolizumab avelumab durvalumb ipilimumab drug
function prevent tumor activ immuno-suppress
pathway becom mainstay treatment number
cancer particular blockad increasingli use
standard care front-lin set combin chemotherapi
melanoma non-smal cell lung cancer nsclc base larg
number on-going clinic trial involv drug expect label
today checkpoint antibodi continu expand new indic
forese futur
checkpoint antibodi undeni posit impact
thousand patient patient respond treatment see exhibit
reason failur typic fall three distinct categori insuffici
expans tumor-react t-cell inadequ function tumor-react t-
cell ineffect t-cell memori function british journal cancer
pp cancer molecular signatur neoantigen
make immunolog distinct healthi tissu therefor like
poor candid checkpoint antibodi therapi similarli impair neoantigen
process and/or present keep patient abl mount
effect respons cancer even help checkpoint
antibodi inadequ t-cell function like aris immuno-suppress
condit present tumor microenviron heterogen popul
cell compos cancer cell well non-cancer stromal cell recruit
tumor support surviv checkpoint antibodi aim help overcom
local immuno-suppress condit exist within tumor
checkpoint antibodi counteract safeti mechan human
evolv prevent immun cell especi t-cell destroy
healthi tissu current repertoir approv immun checkpoint inhibitor
act differ point t-cell matur distinct physic locat
summar exhibit blockad act nave t-cell lymph
node promot sustain t-cell activ prolifer contrast
blockad act interfac tumor cell effector t-cell
counter signal instruct activ t-cell stand cancer
cell take advantag immun check balanc upregul specif
factor suppress bodi immun respons
beyond grow list checkpoint hardwir
immun system help maintain self-toler modul durat
amplitud immun respons natur review cancer pp
immun checkpoint biolog remain activ area research
see field potenti lucr biotech compani compugen
capabl identifi new checkpoint target frequent co-
opt tumor
exhibit blockad promot sustain t-cell activ
given mechan action autoimmun common side effect
checkpoint antibodi unfortun block
pathway often come slew undesir autoimmune-rel side
effect coliti endocrinopathi hepat dual checkpoint
blockad inhibitor shown dramat respons rate
patient metastat melanoma respons rate high half
patient experienc signific toxic treatment regimen engl
among best-character checkpoint
mean pathway exploit cancer cell escap
mechan tumor compens activ altern co-inhibitori
immun checkpoint associ
adapt resist blockad see cancer immunol
believ drug
singl pathway ineffect major patient fulli overcom
tumor immuno-suppress believ combin appropri checkpoint
inhibitor must deploy
see compugen innov space focu
identifi new previous underappreci checkpoint target could
safe deploy combin regimen methodolog summar
exhibit util rel unbias predict comput method search
gene bear hallmark structur and/or sequenc similar
express pattern checkpoint modul hit identifi via comput
screen subject extens function character advanc
lead target clinic compugen methodolog identifi target
uniqu pursu compugen polioviru receptor-rel
ig-contain pvrig well competit target like t-cell
immunoreceptor ig itim domain tigit also pursu
biopharma giant includ bristol-my squibb roch merck addit
intern pvrig tigit program compugen discov
sever undisclos myeloid target may help tumor evad immun
exhibit compugen iter approach checkpoint target discoveri
ancillari checkpoint amen combin therapi
tigit pvrig consid secondari co-inhibitori receptor
secondari checkpoint includ tigit pvrig
consid less crucial t-cell regul part
gene encod secondari checkpoint knock mice
without lead fatal autoimmun critic
maintain self-toler throughout t-cell develop secondari co-
inhibitori receptor play tightli defin role regul t-cell activ
particularli site inflamm immun may
cancer evolv becom resist primari
checkpoint take advantag secondari co-inhibitor process term
adapt resist well tumor may simpli reli secondari
pathway other secondari co-inhibitori checkpoint play less
domin role protect auto-immun
anticip may amen combin immunotherapi
rel safeti toxic co-inhibitori immun checkpoint schemat
illustr exhibit tigit predict rel favor safeti
profil clinic
exhibit hierarchi select co-inhibitori receptor
immun checkpoint express t-cell consid co-activ
oppos co-inhibitori class includ gitr
sever other across industri number drug target co-activ
co-inhibitori checkpoint early-stag clinic develop
believ number safe effect checkpoint antibodi combin
clinic verifi next year howev anticip
optim checkpoint combin could specif underli cancer
combin therapi i/o
acknowledg drug t-cell checkpoint may solv part
problem highli multifacet immunosuppress influenc
mdsc macrophag secret potent anti-inflammatori cytokin
polar t-cell develop effector t-cell regulatori t-cell treg
counter abil cytotox t-cell kill cancer cell
immunoth cancer jul target immunosuppress
cell repres excit new avenu improv i/o compugen earli
stage i/o pipelin includ myeloid target could ultim pair nice
could help
overcom resist therapi
compugen two lead oncolog asset anti-pvrig antibodi
anti-tigit antibodi target t-cell co-inhibitori receptor involv
signal network pvrig tigit identifi target base
structur similar famili includ
along express data indic upregul variou tumor
tigit pvrig highli analog may indic
evolutionarili conserv mechan action tigit pvrig compet
dnam activ receptor express t-cell ligand
pvr present either cancer cell antigen-
present cell tigit higher affin pvr competitor dnam
illustr exhibit dnam activ either pvr
pvrig compet dnam ligand maxim t-cell
respons compugen develop antibodi block tigit/pvr
interact interact therebi encourag dnam-
exhibit pvrig tigit ligand
compugen corpor present januari modifi immunol
compugen independ identifi tigit co-inhibitori checkpoint
publish manuscript year group genentech
publish target proc natl usa oct
immunol howev
compugen identifi pvrig potenti import player signal
network tigit subject intens preclin studi concis
review see immun may sever drug target
tigit phase trial see exhibit contrast character
pvrig almost entir perform in-hous compugen
compani hold card close chest howev preclin data
compugen present pvrig support role import checkpoint
may actual play domin role tigit varieti cancer
preclin model describ display synergi
antibodi believ target
axi could combat problem adapt resist
slate enter clinic like follow
suit
believ big biopharma good reason interest tigit big
biopharma may miss critic part stori ignor pvrig
natur bind partner tigit pvr lesser extent
commonli upregul varieti malign includ endometri
ovarian lung colorect kidney prostat cancer knockout tigit
tigit role dampen immun respons confin cytotox effector
t-cell tigit also upregul treg function promot rather
obstruct treg activ often tigit express elev
helper t-cell treg effector t-cell isol tumor
compar cell isol peripher blood normal adjac tissu see
exhibit
exhibit tigit express differ lymphocyt subset tumor
tigit immuno-suppress role sole depend abil
outcompet activ receptor dnam bind pvr engag
pvr tigit cytoplasm tail touch signal cascad downregul
key compon t-cell receptor suggest tigit possess intrins
tigit/pvr interact releas brake t-cell also
promot dnam-medi activ t-cell cancer cell dec
like tigit express activ t-cell express may
indic t-cell exhaust tigit may actual play activ role
promot adapt resist inhibit exampl t-cell
melanoma patient found upregul tigit day incub
antibodi presenc antigen howev
express upregul perform experi
anti-tigit antibodi exhibit
note blockad anti-tigit antibodi appear improv t-cell activ
measur ifn secret blockad combin tigit
antibodi improv respons agent alon exhibit
collect believ data provid rational drug
pathway patient previous treat
exhibit anti-tigit combin increas t-cell activ
pvrig miss piec tigit puzzl
compugen gather evid suggest pvrig play underappreci
role signal network target pvrig could
essenti effect drug pathway tigit pvrig knockout
confer poster abstract discuss believ dual
blockad tigit pvrig checkpoint effect drug
either checkpoint alon compugen first identifi pvrig
target compani strateg focus resourc push
clinic competitor evalu anti-tigit antibodi phase
trial anticip anti-tigit antibodi may display good safeti modest
efficaci clinic perform best pair anti-pvrig
antibodi
much like tigit pvrig express activ t-cell express
directli correl tigit express tumor see exhibit howev
express pvr ligand appear depend cancer
rel pvr express highest uterin ovarian
endometri cancer well tripl neg breast cancer prostat
cancer compugen observ pvr highli express
antigen present cell apc lung cancer taken togeth believ
data suggest specif type cancer pvrig may
import tigit signal network
exhibit pvrig tigit express correl express ligand
compugen analyz pvr tigit express across larg
panel solid tumor note express elev endometri
lung breast colon cancer rel normal tissu suggest
interact especi relev case see exhibit
interestingli inhibit proven larg ineffect mani
tumor suggest secondari co-inhibitor may play especi import
role promot tumor escap
exhibit express elev healthi tissu certain tumor
take closer look express profil pvrig pvr
tigit see exhibit predict lung endometri tumor may
particularli depend signal network combin therapi
could particularli effect cancer
exhibit express tigit/pvr variou tumor
pvrig tigit bird feather
similar tigit compani report pvrig express increas
function t-cell activ track indic t-cell exhaust
among immun cell pvrig express induc effector t-cell
well helper t-cell lesser degre b-cell note pvrig
also highli express activ nk cell exhibit interestingli pvrig
express induc nk cell trigger antibody-depend cellular
cytotox adcc suggest blockad pvrig may
sensit cancer cell therapi herceptin reli adcc
exhibit pvrig upregul distinct immun cell upon activ
much like pvr upregul may also serv mechan
adapt resist checkpoint inhibit antibodi
meet compugen show gener upregul pd-
tumor sampl varieti cancer exhibit
exhibit express elev tumor
aim synergi checkpoint
compugen present abund non-clin evid suggest
potenti synergi pvrig tigit inhibitor even tripl
combin pvrig tigit inhibitor exampl tumor-infiltr
lymphocyt til isol patient lung kidney endometri
cancer show increas t-cell activ measur ifn secret
tumor cell line exposur combin
compar monotherapi interestingli antibodi
activ t-cell compar antibodi pembrolizumab see
exhibit compani test tripl combin tigit pvrig
inhibitor lead robust t-cell activ increas
ifn product rel isotyp control howev note doubl
combin tigit pvrig inhibitor also produc robust respons
may offer bang buck rel tripl combin see
exhibit combin increas potenc
look beyond inf product pvrig blockad abl
retard tumor growth tigit-/- knockout mous model effect
knockout alon wild-typ mice treat similar result
observ antibodi pvrig knockout mous
confer hunter et al oral present believ data support
futur investig combin
blockad cours efficaci safeti combin
must valid clinic process start
monotherapi trial slate begin
exhibit inhibit tumor growth tigit knockout mice
expect enter clinic monotherapi stage
combin antibodi stage see exhibit first-in-
human studi like comer without pre-select base
biomark express tumor sampl expect initi
studi focu safeti defin suitabl dose
strategi subsequ studi stage ic could focu tumor express
elev level preferenti express pvr
believ studi could offer earli opportun object respons
exhibit clinic develop strategi
per discuss manag expect enter clinic
could see first clinic evalu
combin believ compani could streamlin develop
timelin util biomarker-driven strategi
focu tumor type like respond blockad
axi lung endometri cancer across industri median
clinic develop time checkpoint antibodi date
especi rapid month avelumab rel short timelin
month clin cancer dec doi
pvrig tigit checkpoint mean secondari co-
inhibitori checkpoint exploit tumor escap immun system
asid on-going clinic trial tigit inhibitor also
identifi promis target test clinic see exhibit
co-inhibitori checkpoint often group togeth scientif
literatur believ neg posit clinic result
blockad clear read-through tigit pvrig sever differ
regulatori function anatom locat could make certain pathway
relev other given malign opinion util
checkpoint target type cancer must empir valid
clinic
importantli expect earli phase monotherapi studi target
co-inhibitori receptor gener robust clinic respons previous
discuss believ two checkpoint must block combin
maximum efficaci combin display synergi
pvrig tigit tigit synergist suppress antitumor activ
murin model clin invest
implic adapt resist blockad
feb collect studi suggest
adapt resist inhibitor aris multipl altern
exhibit drug target co-inhibitori checkpoint current develop
market opportun
knowledg compugen compani develop anti-pvrig
antibodi complement develop anti-tigit antibodi although
pvrig may play domin role tigit certain tumor current
believ combin repres compani
commerci viabl therapi base avail express profil data
project combin could success refractori lung
market model endometri cancer
assum combin could approv use
patient relapsed/refractori r/r endometri cancer albeit low
probabl success po given preclin stage develop
approxim patient us per seer statist
patient eu per eucan statist die year endometri cancer
set price per treatment us europ less
list price combin ipilimumab nivolumab estim
combin market opportun approxim
assum moder penetr r/r endometri cancer market
project peak us sale peak eu sale translat
risk-adjust revenu approxim anticip us
commerci launch follow eu launch model
profit-shar compugen european commerci partner
endometri cancer market model summar exhibit
exhibit market model combin r/r endometri cancer
market model lung cancer
assum combin could approv use
patient relapsed/refractori non-smal cell lung cancer albeit low
po given preclin stage develop
approxim patient us per seer statist
patient eu per eucan statist die year nsclc set
price per treatment us europ less
list price combin ipilimumab nivolumab estim combin
market opportun approxim
given nsclc extrem crowd indic area assum modest
penetr r/r nsclc popul project peak us sale
peak eu sale translat risk-adjust revenu
anticip us commerci launch follow eu
launch model profit-shar compugen
european commerci partner nsclc market model
summar exhibit
exhibit market model combin r/r nsclc
put checkpoint modul work
flip side oncolog portfolio compugen singl disclos
program autoimmun diseas checkpoint inhibitor use
unleash immun system tumor checkpoint agonist util
therapeut re-appli brake strategi work
checkpoint abatacept bristol-my squibb fusion protein consist
extracellular domain join fc region immunoglobin
approv treatment sever autoimmun disord includ
compugen eye similar strategi checkpoint cgen-
involv recent describ
literatur immunol
antibodi licens bayer treatment cancer current ind-
enabl studi fusion protein slate
develop compugen varieti autoimmun disord see exhibit
exhibit act agonist
adapt compani poster present may
like tigit pvrig checkpoint discov use
compugen structur homolog search algorithm express
monocyt myeloid progenitor activ migrat site
inflamm assist antigen present phagocytosi
monocyt implic pathogenesi autoimmun diseas includ
rheumatoid arthriti ra multipl sclerosi ms although natur ligand
remain unknown fact bind activ t-cell
suggest ligand may co-inhibitori receptor t-cell
mous model ra dose appear amelior symptom
in-lin achiev anti-tnf antibodi exhibit left panel
standard-of-car class drug commonli prescrib ra patient intriguingli
co-cultur monocyt t-cell isol ra patient show
induc dose-depend reduct tnf secret exhibit
right panel isotyp control effect
exhibit show activ preclin model ra
work recent publish compugen academ collabor
found promot toler induct treg mous model
ms short two-week cours abl re-establish long-term
antigen-specif toler depend treg howev
immunosuppress effect abolish antibodi
treg-promot cytokin tgf co-administ exhibit
exhibit activ depend regulatori t-cell
believ work highlight potenti act key
driver autoimmun suppress antigen-specif respons cgen-
may suppress autoimmun sourc rang autoimmun
disord highlight checkpoint exploit reduc
disease-specif inflamm without pan-immunosuppress effect
result tnf inhibitor adalimumab find earli data
surround excit choos ascrib valu
program time due earli stage develop
compugen activ seek protect therapeut candid composit
matter patent cover compani checkpoint target method
use patent cover potenti therapeut indic februari
compani issu patient issu us pend
patent applic file us issu patent expir
year believ issu pend patient could
suffici defend persecut caveat
lawyer key patent us cover compani anti-
pvrig antibodi issu
compugen approxim million cash cash equival
market secur end believ compani suffici
resourc fund oper late includ multipl dilut
capit rais model could sustain compani profit
project loss
per share respect expect see increas cash burn
associ increas sg reflect compani plan ind
file
believ combin therapi could initi
commerci us eu gener
revenu compugen basi year revenu ep
introduc estim increas
introduc estim increas
assum cog compugen antibodi
believ in-lin monoclon antibodi
cohen-dayag ph presid chief execut offic
chief oper offic
svf corpor busi develop
vice-president antibodi head compugen usa
presid chief execut offic
dr cohen-dayag join compugen held posit
director diagnost vice-president diagnost biomark drug target vice-president
dr cohen-dayag appoint togeth martin gerstel co-
ceo compugen dr cohen-dayag appoint compugen
presid ceo prior join compugen head
member execut manag mindsens biosystem dr cohen-
dayag hold sc biolog ben-gurion univers sc
chemic immunolog ph cellular biolog weizmann institut
scienc addit dr cohen-dayag director ramot tel aviv
univers ltd director iati isra advanc
chief oper offic
mr krashin join compugen chief offic compugen
appoint also chief oper offic mr krashin
year experi capit market financ busi develop
serv chief financi offic public privat compani
recent anyclip media spacenet inc mr krashin also cfo
gilat satellit network led compani global financ relat
administr mr krashin certifi public account began
profession career kesselman kesselman pwc israel mr krashin
hold busi administr account colleg
svf corpor busi develop
kirk christoffersen join compugen senior vice presid corpor
busi develop decemb prior join compugen mr
christoffersen presid apollo bioconsult boutiqu life scienc
consult firm led corpor develop
globeimmun inc initi senior director vice presid
corpor develop prior globeimmun mr christoffersen held
leadership posit corpor develop market three
biotechnolog compani includ
nexstar pharmaceut mr christoffersen earn undergradu degre
univers michigan daniel colleg
busi univers denver
vice-president antibodi head compugen usa
dr hunter bring compugen usa inc year scientif expertis
mab research genom translat medicin vice presid antibodi
research develop compugen usa inc head lead
gener preclin develop mab therapeut compugen-
discov target prior join compugen dr hunter serv senior
director xoma manag strateg function activ relat build
robust preclin mab pipelin began industri career millenium
pharmaceut special oncolog therapeut research
dr adewoy join compugen recent
serv clinic director oncolog clinic research oncolog
leadership held posit increas respons project
clinic lead multipl phase program idelalisibth first
kinas delta inhibitor approv relaps cll sll follicular lymphoma
andecaliximab inhibitor acalisib prior gilead
clinic research medic director oncolog amgen inc global
medic monitor initi registr trial bispecif antibodi
blinatumomab blincyto sever phase studi evalu vegf
inhibitor motesanib trebananib patient solid tumor dr adewoy
complet fellowship hematology/oncolog boston medic center
complet resid intern medicin meharri medic colleg dr
adewoy receiv medic degre univers jo nigeria
fellowship train hematolog laboratori medicin univers
colleg hospit ibadan nigeria dr adewoy board certifi american
board intern medicin medic oncolog hematolog intern
sec file oppenheim co research
figur thousand except per share us sale eu sale good sold expens research develop market busi develop gener administr oper loss incom financ incom loss incom tax incom incom loss per share share outstand co inc mark breidenbach cgen outperform
sec file oppenheim co research
figur thousand except per share cash equival short-term bank account receiv prepaid current long-term prepaid sever pay properti equip account payabl accru expens trade current accru sever non-curr equitytot stockhold liabil stockhold co inc mark breidenbach compugen ltd
stock price compani mention report
